Peptides, ‘Wellness’ and the Law
Dr Harry Singh says UK Medical Professionals need a regulatory reality check when it comes to peptides
Peptides are fast becoming a key area of interest in aesthetic and regenerative medicine, attracting growing attention from practitioners and patients alike.
From industry conferences to clinic social media feeds, names like BPC-157, Ipamorelin, and CJC-1295 are being discussed with a fervour that rivals the early days of botulinum toxin. For many clinicians, these compounds represent the cutting edge of “wellness” and “longevity” – promising fat loss, injury repair, and anti-ageing benefits that go beyond traditional aesthetics. However, enthusiasm for innovation must never outpace regulatory compliance. As medical professionals, we operate within a strict legal framework designed to protect patients, not to stifle progress. The current “wild west” environment of peptide prescribing in the UK is on a collision course with the Medicines and Healthcare products Regulatory Agency (MHRA). This article serves as a reality check: a clear, evidence-based guide to the legal status of these substances and the professional risks involved in dispensing them.
The regulatory reality in the UK
The starting point for any discussion on peptides is the Human Medicines Regulations 2012. The law is unambiguous: for a medicinal product to be placed on the UK market, it must hold a Marketing Authorisation (licence) from the MHRA. This licence is the gold standard of safety, efficacy, and quality. Currently, the vast majority of “wellness” peptides marketed in the UK – including BPC-157, TB-500, MOTS-C, Epitalon, and various growth hormone secretagogues – are unlicensed medicines. They have not been assessed by the MHRA for human therapeutic use.
While some peptides (like insulin or licensed GLP-1 agonists) are stalwarts of modern medicine, the specific compounds flooding the wellness market are, legally speaking, unapproved drugs.
The myth of “research use only”
A dangerous misconception circulating in professional groups is that labelling vials as “Research Use Only” (RUO) or “Not for Human Consumption” provides a legal shield. This is false. The MHRA and the courts look at the context of supply, not just the label. If a clinic purchases peptides labelled “for research only” but then advertises them on a patient-facing website, discusses dosage protocols in consultations, or implies therapeutic benefits (such as “injury recovery” or “immune support”), the “research” defence collapses. In the eyes of the law, if a product is presented for treating or preventing disease, or for restoring, correcting, or modifying physiological functions in humans, it is a medicinal product. Using the “research” loophole to supply patients is a transparent attempt to circumvent the Human Medicines Regulations, and regulators are fully aware of it.
The ‘Special Clinical Need’ exemption: When it applies (and when it doesn’t)
Many clinicians justify peptide prescribing under the “specials” exemption. Regulation 167 of the Human Medicines Regulations 2012 does allow for the supply of unlicensed medicines, but only under strict conditions known as the “specials” regime. This exemption is designed for exceptional clinical circumstances, not routine business models. For Regulation 167 to apply, there must be a “special clinical need” that cannot be met by a licensed alternative. Crucially:
- The prescription must be for an individual, named patient.
- It must be in response to an unsolicited order (you cannot market the product to generate demand).
- There must be no available licensed medicine that meets the patient’s needs. Using Regulation 167 to hold bulk stock of unlicensed peptides for a “wellness clinic” menu, or to treat conditions like “general ageing” where licensed lifestyle interventions exist, is a misapplication of the law. “Cost,” “convenience,” or “patient demand” are not valid special clinical needs.
Prescriber responsibility and GMC expectations
When you step away from licensed medicines, you step away from the safety net of the regulatory system. The General Medical Council (GMC) is explicit on this matter. In its guidance “Good practice in prescribing and managing medicines and devices” (2021), the burden of proof shifts heavily onto the prescriber. If you prescribe an unlicensed peptide, you must:
1. Be satisfied that there is sufficient evidence or experience to demonstrate its safety and efficacy (social media anecdotes do not count as evidence).
2. Take full responsibility for the patient’s care, monitoring, and any adverse events. Unlike with licensed drugs, you cannot rely on the manufacturer’s liability; the buck stops entirely with you.
3. Record your justification, noting why no licensed alternative was suitable.
4. Obtain and document informed consent, ensuring the patient explicitly understands they are receiving an experimental, unlicensed product with unknown long-term risks. Failure to meet these standards doesn’t just risk a civil claim; it questions your fitness to practise.
Enforcement is not theoretical
If you believe regulatory action is unlikely, look no further than the events of October 2025. In a landmark operation, the MHRA’s Criminal Enforcement Unit, supported by police, raided a facility in Northamptonshire. This was the UK’s first discovered illicit manufacturing site for weight-loss medicines. Officers seized over 2,000 pre-filled pens labelled as Retatrutide and Tirzepatide – peptides that are either unlicensed or prescription-only – along with raw chemicals and packaging equipment. The street value exceeded £250,000.
The MHRA’s Head of Criminal Enforcement stated clearly that they “will stop at nothing” to dismantle networks putting profit before safety. This raid signals a significant escalation. The regulator is actively targeting the supply chain of unlicensed peptides. Clinicians found to be part of that chain – whether by purchasing from unregulated labs or supplying patients illegally – face criminal prosecution and professional ruin.
Professional, ethical, and patient-safety considerations
Beyond the law, we must consider our ethical duty. The medical profession is built on the principle of primum non nocere(first, do no harm). Many of the peptides currently in vogue have promising mechanisms of action in animal models but lack robust human safety data. By administering them, we are effectively conducting uncontrolled experiments on our patients.
• Purity risks: “Grey market” peptides often come from underground labs with no Good Manufacturing Practice (GMP) oversight. Contamination with heavy metals, endotoxins, or wrong dosages is a real risk.
• Long-term safety: The proliferative effects of some growth factors raise theoretical concerns about oncogenesis (cancer growth) that have not been ruled out by long-term trials. Prioritising “hype-driven medicine” over evidence-based care erodes public trust in our profession. True regenerative medicine is a disciplined science, not a menu of unregulated injectables.
Practical guidance for clinicians
To navigate this complex area safely, I urge my colleagues to adopt a rigorous approach:
1. Verify licence status: profound diligence is required. Check if the product has a UK Marketing Authorisation. If not, treat it with extreme caution.
2. Audit your supply chain: If you are buying “medical” products from a website that sells “research chemicals,” stop immediately. Legitimate medical supplies do not come with “not for human consumption” disclaimers.
3. Review your marketing: Remove any patient-facing advertising of unlicensed peptides. Promoting an unlicensed medicine to the public is a criminal offence.
4. Stick to the evidence: Prioritise approved, licensed treatments. If you must prescribe off-label or unlicensed products (e.g., for a rare, specific need), ensure your documentation and consent processes are watertight and compliant with GMC paragraph 106.
5. Seek advice: If you are unsure about the status of a treatment, consult your medical defence organisation or a specialist healthcare lawyer before proceeding.
Conclusion: Innovation with Integrity
There is a place for innovation in medicine. Many of today’s standard treatments began as experimental therapies. However, that transition must happen through proper clinical trials and regulatory approval, not through direct-to-consumer sales in aesthetic clinics. As leaders in the private medical sector, we have a choice. We can chase the latest grey-market trend and risk our licences, or we can lead with integrity, advocating for safe, regulated, and evidence-based progress. Let us choose the latter, protecting our patients and the reputation of our profession.
References
1. The Human Medicines Regulations 2012, S.I. 2012/1916.
2. General Medical Council. (2021). Good practice in prescribing and managing medicines and devices.
3. MHRA. (2014). The supply of unlicensed medicinal products (“specials”): Guidance Note 14.
4. MHRA. (2025). MHRA smashes major illicit weight loss medicine production facility in record seizure. [Press Release]. October 2025.